Elvitegravir

PD Dialyzability: Unlikely

Pharmacokinetic Parameters [1] [2]

	Elvitegravir
Molecular Weight (Da)	447
Plasma Protein Binding (%)	98 - 99
Volume of Distribution (L/Kg)	Unknown
Hepatic Metabolism	CYP3A (major), UGT 1A1/3
Excreted Unchanged (%)	Unknown (6.7% as metabolites)
Half-Life; Normal Renal Function (hours)	8.7
Half-Life; ESRD (hours)	Unknown

CAPD/CCPD Dosing: [1] [2]

No dosing recommendation for PD population was found in literature. However, due to major hepatic metabolism, extensive protein binding and minimal renal excretion of unchanged drug, it is unlikely that dosing adjustment is required.

Literature Summary:

None identified

References

[1]	(1, 2) Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-672.

[2]	(1, 2) Tseng A. Selected properties of Elvitegravir. Immunodeficiency Clinic [Internet]. 2014 Dec [cited 2018 Jan 19]. 1-6. Available from www.hivclinic.ca